A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements

Simply Wall St.12-01

CG Oncology (CGON) is making headlines after announcing two late-breaking podium presentations on topline clinical trial results for cretostimogene at the upcoming Society of Urologic Oncology Annual ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588484718?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-01 01:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588484718","market":"us","top_or_hot":-1,"title":"A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements","media":"Simply Wall St.","content":"<div>\n<p>CG Oncology (CGON) is making headlines after announcing two late-breaking podium presentations on topline clinical trial results for cretostimogene at the upcoming Society of Urologic Oncology Annual ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncologys-cgon-valuation-following-new-clinical\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-01 01:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncologys-cgon-valuation-following-new-clinical><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CG Oncology (CGON) is making headlines after announcing two late-breaking podium presentations on topline clinical trial results for cretostimogene at the upcoming Society of Urologic Oncology Annual ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncologys-cgon-valuation-following-new-clinical\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncologys-cgon-valuation-following-new-clinical","article_id":"2588484718","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/a-look-at-cg-oncologys-cgon-valuation-following-new-clinical","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2588484718","pubTimestamp":1764522635,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CG Oncology (CGON) is making headlines after announcing two late-breaking podium presentations on topline clinical trial results for cretostimogene at the upcoming Society of Urologic Oncology Annual Meeting. This news has sparked renewed investor interest.\nSee our latest analysis for CG Oncology.\nMomentum has clearly been building for CG Oncology, especially as topline clinical data and boardroom changes have turned heads. The share price return over the past 90 days stands out at 67.2%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4135":"资产管理与托管银行","CGON":"CG Oncology Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","CG":"凯雷"},"translate_title":"新临床试验数据公布后CG Oncology(CGON)的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGON":1.5,"CG":1.5,"DCF":1},"content_text":"CG Oncology (CGON) is making headlines after announcing two late-breaking podium presentations on topline clinical trial results for cretostimogene at the upcoming Society of Urologic Oncology Annual Meeting. This news has sparked renewed investor interest. See our latest analysis for CG Oncology. Momentum has clearly been building for CG Oncology, especially as topline clinical data and boardroom changes have turned heads. The share price return over the past 90 days stands out at 67.2%, while the year-to-date gain of 54.8% signals robust investor confidence. Despite these recent moves, the longer-term total shareholder return over one year is 29%. This reflects both excitement and caution around future milestones. If new clinical data has you curious about where the next breakthroughs might come from, there is a world of opportunity in healthcare. Find your next idea with our See the full list for free. With new data and boardroom shifts pushing the share price higher, investors are now left to wonder whether CG Oncology is still trading below its true potential or if the recent gains mean the market has already factored in future growth. AdvertisementPrice-to-Book of 5.3x: Is it justified? CG Oncology currently trades at a price-to-book ratio of 5.3x, nearly double the US Biotechs industry average of 2.8x. This premium suggests investors are pricing in substantial growth or a unique position in the sector at the last close price of $44.84. The price-to-book ratio measures how much investors are paying for each dollar of book value. In biotech, where tangible assets are limited and future prospects drive value, a higher ratio often reflects expectations for clinical advances and pipeline potential. While CG Oncology’s ratio is elevated versus industry norms, the company is classified as a late-stage clinical biopharma and boasts rapid annual revenue growth forecasts. It is important to note that the market is ascribing greater value than peers. This may reflect optimism, but also increases expectations for future success.  Compared to peers, CG Oncology appears expensive on this metric, but may offer differentiated pipeline prospects. If a fair value ratio were available, it could indicate where sentiment might ultimately settle.\n See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of 5.3x (OVERVALUED) However, clinical trial setbacks or a slower than anticipated regulatory path could quickly temper the optimism currently fueling CG Oncology’s share price. Find out about the key risks to this CG Oncology narrative. Another View: What Does the DCF Model Suggest? While CG Oncology appears expensive compared to its industry on a price-to-book basis, the SWS DCF model tells a different story. According to this approach, CG Oncology's current price sits 88.6% below its estimated fair value. This suggests the market might be underestimating its true potential. Could deeper value be hiding beneath the surface optimism, or does this model rely on projections that may not materialize? Look into how the SWS DCF model arrives at its fair value. CGON Discounted Cash Flow as at Nov 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 914 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own CG Oncology Narrative If you have your own perspective, or would like to interpret the data differently, it is easy to generate your own insights in just a few minutes with Do it your way. A great starting point for your CG Oncology research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. Looking for more smart stock ideas? Why stop at just one opportunity? Make bold moves by exploring other high-potential stocks chosen for their growth, innovation, or strong income streams before the market catches on.  Benefit from the explosive potential of artificial intelligence advancements by reviewing these 25 AI penny stocks, which are set to shape tomorrow’s tech landscape. Boost your portfolio’s income with these 15 dividend stocks with yields > 3%, featuring stable companies offering attractive yields above 3%. Capitalize on under-the-radar gems by searching through these 3561 penny stocks with strong financials, combining affordable entry points with solid financial fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588484718","isCrawlerRequest":true}